Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Zero increase this week
Just to clarify, you're no longer invested in Todos?
Outstanding Shares Update - 9/10/21
https://www.otcmarkets.com/stock/tomdf/security
Wait and watch how your investment will go.
No reason for name-calling, dude, and getting your post deleted. I provided links to numerous filings showing the options were executed for the Provista purchase. Just because you weren't aware of them doesn't mean the CEO is lying. Information is given to investors in numerous ways, not just 8-K filings. I was just wondering why you didn't acknowledge your claims were not accurate, as per your post below.
What don't you understand about the filings? The option of 1/6/20 was never executed !!! Filing of the 8K on 4/23/21 was the purchase of Provista for 7.5 million. On 8/2/21 GC claims Provista was aquired for 10 million. When asked for clarification he staes the option of 1/6/20 that wasn't executed. What don't you understand??? I never asked your opinion. You gave it incorrectly and I responded. Why do you continue to support GC's misleading statments? Paid pumper???
I just post the updates. I don't know any more than you, but the quarterly filing may shed some light.
I guess GC is lying again, like he did with the Provista purchase.... except he didn't lie. I noticed there was no response to my last post to you.
https://investorshub.advfn.com/boards/replies.aspx?msg=165564082
Outstanding Shares Update - 9/3/21
https://www.otcmarkets.com/stock/tomdf/security
Reopening Schools - A Battleground of Policy Implications Without Surveillance Testing
by Gerald Commissiong
September 2, 2021
https://www.linkedin.com/pulse/reopening-schools-battleground-policy-implications-commissiong/
The violent surge of the Delta variant has taken many school policy makers by surprise. In the spring of this year, the Biden Administration allocated $10 billion for testing to help get kids back to school to experience in-person learning before the summer break. This was part of the American Rescue Plan and its goal to reopen the schools. Studies researched by the CDC in support of this plan showed 0.7% to 2.0% infectivity within the school population even in areas with high community transmission rates. The concept behind the testing was to limit the community spread of the virus within the schools. Let’s face it, there were major challenges in deploying the plan broadly throughout the US in the second quarter of 2021, but ultimately when implemented surveillance testing appeared to work and there was very little community spread. Surveillance was run at the local level, which is why there are no national statistics to rely upon, but a Nature Article published in July 2021 confirmed that there was less than 1% infectivity in children with full mitigation measures in place. Without masks and ventilation one school in Utah recorded an infectivity rate of 13.2% in students and 16.6% in staff. Clearly mitigation measures work, but we can’t give all the credit to testing because it was a combination of mask usage, ventilation, social distancing, and hand washing.
Changes at the CDC this spring have dramatically altered our understanding of the risk the Delta variant poses to adults and children and I hope to shed some light on the topic by looking at some case studies. On May 14, 2021 the CDC stopped tracking symptomatic breakthrough infections. If you are wondering how one stat could be so influential it is because breakthrough infections are essentially a measure of the effectiveness of the vaccines against transmission. We have practically no data at the national level and I pointed this out in my last article. We really need this surveillance data because it will help us better understand the effectiveness of the vaccine and lead us to data driven policy guidance. Without the data we have to look elsewhere.
Public Health England Report
We can get a glimpse of how effective our policies will be for the coming school year by looking at the Public Health England Report that breaks out some useful data for consideration. The Delta variant became the dominant strain by the third week of May while kids were still in school. The United States lagged the United Kingdom by approximately one month and most were on summer break.
It may be hard to see on this chart, but on week 20 which represents May 23, we saw the first uptick in school cases that corresponded with Delta becoming the dominant strain. As the kids remained in school the infections spiked exponentially. At week 25 which represents June 27, the new cases were experiencing exponential growth and it was probably fortunate that school ended.
The graph above provides an assessment of the infectivity rate we could see in schools using the existing protocols. Here we see that within 6 weeks the infectivity rate could topple 10%. The United States and England use similar protective protocols which means that this study likely represents a good estimate of what to expect in the US.
It's unclear what policy makers are going to do at this point. Will they go back to distance learning if the infectivity level rises? What level is unacceptable and triggers this? Right now, it's unclear if they are even going to do testing!
Policy Implications
The American Rescue Plan which created a framework to return to school with closely monitored surveillance testing ended. There are currently no federal programs or policy recommendations at the Federal Level except from the CDC. The CDC still believes in surveillance testing yet they are not aggregating any data. Their recommendations are based on studies done last year before the arrival of the Delta variant. There are 13,000 school districts and each of them has a unique policy on how to handle the reopening according to Randy Weingarten with the Federation of Teachers. It is becoming increasingly clear with the data from Israel how dangerous the Delta variant has become. The protection from the vaccines to the Delta variant is considerably less than what many expected. The data from the UK in schoolchildren was alarming at how quickly the infectivity could rise. While this outlook appears gloomy, we believe surveillance testing along with contact tracing might be able to quell the community spread within our schools and universities.
Surveillance Testing - Path Forward
The real issue is the lack of a standing federal mandate for surveillance testing. We had a mandate 6 months ago, but that has since expired. The American Rescue Plan also came with a pot of testing money. Without this government backing, school districts may be forced to craft policy according to their budget. Testing isn't a political hot button and all parties regardless of their affiliation tend to agree that testing is a socially acceptable practice. Since the return to school policy is so embroiled at this time, perhaps we should start with a topic like testing where there is common ground.
Ideas like vaccination mandates for children without going through testing have no business being in the debate right now especially when an FDA approved vaccine for children under 12 doesn’t even exist. Moreover the existing vaccination is unlikely to stem community spread. Given the recent transmissibility data on the Delta variant we have to stop doubling down on a vaccination-will-fix-all strategy.
HHS Acting Secretary Norris Cochran really had the right idea when it comes to testing.
“COVID-19 testing is critical to saving lives and restoring economic activity. As part of the Biden Administration’s National Strategy, HHS will continue to expand our capacity to get testing to the individuals and the places that need it most, so we can prevent transmission of the virus and defeat the pandemic.” - Norris Cochran HHS Acting Secretary
We think it's time to end the debate and move forward on something we all agree on, that is extensive surveillance testing.
We desperately need data on this Delta variant with respect to the effectiveness of the vaccine and the extent of the community spread within our general population and schools. The administration is clearly operating at a disadvantage without any federal plan to encourage widespread surveillance testing. Since it's clearly going to be mandatory in schools this would be an ideal way for the government to pay for the testing which would enable it to get the data on how the variants are spreading while monitoring and protecting our children. The government would be the central repository of the data in this scenario giving it a look at COVID-19 over a vast geographical region.
By mandating surveillance testing in schools we will be protecting our children and getting valuable information on the spread of the variants. A win for the country and a win for our schools and children.
Provista Diagnostics is capable of handling large government contracts because it invested in automation after COVID infections started to dwindle. While other retooled their labs Provista saw the need for additional testing capacity should a third wave occur. It’s here. The lab can also do variant testing to track what’s there and uncover any new rising variants of concern. The lab is also capable of quantifying the level of neutralizing antibody levels that are capable of thwarting a delta virus infection. This is called the cPass neutralizing antibody test. We are also working on validation of the Tollo Test which will measure the active COVID-19 infection via the 3CL protease test.
NEWS: Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test
https://investor.todosmedical.com/news-events/press-releases/detail/128/todos-medicals-cliacap-lab-provista-completes
· CEO Gerald Commissiong to appear on Yahoo! Finance Live Today at 4:10 pm EDT
· Respiratory panel critical as Back to School begins heading into Fall 2021
· RSV and Influenza expected to make resurgence with low masking compliance
New York, NY, and Tel Aviv, ISRAEL, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Quidel Lyra Influenza A & B and the Lyra RSV & hMPV PCR kits into production alongside COVID PCR tests currently being run (together the “Provista Respiratory Panel”) and expects this new respiratory panel to be launched in September 2021. The validation coincides with the recent validations for the cPass semi-quantitative COVID neutralizing antibody test and the Kogene COVID variant detection kits also being launched in September 2021. This positions Provista to now offer a turnkey solution for healthcare, businesses, school systems, government agencies, and others seeking access to a high-quality comprehensive lab to support testing programs as the US economy continues its reopening heading into the Fall of 2021.
CEO Gerald Commissiong will appear on the Yahoo! Finance Live Show at 4:10 pm EDT today, Wednesday September 1st, 2021 to discuss the recent developments at Provista as well as its plans to advance Tollovir, the Company’s oral, dual mechanism 3CL protease inhibitor/anti-cytokine antiviral drug candidate for COVID-19 treatment currently in a Phase 2 clinical trial for hospitalized COVID-19 patients in Israel. The Company is preparing to expand its trials to include pivotal Phase 2/3 trials in both hospitalized and non-hospitalized COVID patients that it expects to initiate in the coming weeks.
“As the nation heads back to school, and many children head back into classrooms for the first time in nearly 18 months, there is significant risk for a resurgence in influenza and RSV viruses that declined dramatically during the pandemic,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We’ve already seen evidence of a resurgence in RSV over the summer in certain southern states in the US, and now heading into Fall 2021 flu season it is critical that pediatricians are able to make accurate diagnoses so that kids can be quarantined if needed due to COVID, or they can be quickly returned to the classroom when initial symptoms resolve in the event of another respiratory illness as often happens during the school year. Children’s immune systems have largely not been exposed to many respiratory pathogens over the last 18 months, and so it is important that communities are prepared to deal with multiple respiratory illnesses that present with similar symptoms. The major challenge pediatricians will be facing this fall with point of care antigen tests often used for respiratory pathogens is that, similar to COVID, many respiratory illness antigen tests produce false negative results early on in the disease process, and therefore many diagnoses are caught at a second doctor’s visit when symptoms persist or are never properly diagnosed, which is highly frustrating for parents, physicians and patients. The CDC recently updated its guidance to encourage COVID and flu testing simultaneously, and we’ve taken that one step further by adding RSV and hMPV to our PCR respiratory panel because of the dramatic and unexpected rise of these respiratory pathogens over the summer of 2021. By working with Provista, physicians will be able to use the same specimen sample collected for COVID to get highly accurate lab results using PCR for COVID, influenza A & B, RSV and hMPV, so they can have confidence on a treatment plan and the timing of when kids can be returned to the classroom.”
Todos sees a large market opportunity developing for respiratory illness testing that is an adjunct to the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 COVID PCR tests, over 1,500 cPass tests per day, over 5,000 COVID variant tests per day, and over 5,000 respiratory panel tests per day when at full capacity. The CMS reimbursement rate for the Provista Respiratory Panel is $142.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain (COVID-19) testing materials and supplies. The agreements cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
CEO on Twitter - 8/27/21 & 8/28/21
https://www.cdc.gov/mmwr/volumes/70/wr/mm7003e3.htm
Outstanding Shares Update - 8/27/21
https://www.otcmarkets.com/stock/tomdf/security
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
• Company sees a significant market opportunity for reference lab agreements to identify which variant is responsible for positive COVID-19 test results
• Validation paves the way for launch of variant testing at Provista in September 2021
New York, NY, and Tel Aviv, ISRAEL, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Kogene Biotech PCR Variant Test Kit (‘Kogene Variant Kit’) into production and expects to launch variant testing in September 2021. The Kogene Variant Kit is a PCR kit capable of identifying the key mutations associated with specific SARS-CoV-2 variants, including the key P681R mutation identified in the Delta variant, that allows Todos to categorize the lineage of the strain responsible for a positive test result. The test can be completed in as little as one hour, significantly faster than genome sequencing, and is highly scalable with the Tecan® liquid handling automation currently onsite at Provista.
“With the rising number of breakthrough infections caused by the Delta variant that now represents approximately 96% of cases, up from 3% in early July 2021, it has become extremely clear that the United States’ genomic sequencing capabilities are unable to keep up with the sheer volume of demand for classifying which variants are responsible for SARS-CoV-2 infections,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Not only is there significant public health interest in tracking variants, there is also an emerging clinical difference in how physicians may speed the prescription of certain treatments based upon which variant a patient has. This clinical utility, initially seen with the Alpha variant and now more pronounced with the Delta variant, means that we must prepare for the future where we expect new variants, such as the Lambda variant, that appear more capable of escaping vaccination protection and may result in more aggressive treatment strategies. The ability for Provista to scale this test offering rapidly with our automation by reflexing positives for variant analysis and by expanding our reference lab network to confirm which variants are responsible for other labs’ positive results will improve regional understanding of the spread of new variants as they emerge, and provide schools, businesses, and public health officials an ability to react more quickly with policy changes.”
Todos sees a large market opportunity developing for variant testing that will further expand upon the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 PCR tests, over 1,500 cPass tests per day and can complete over 5,000 variant tests per day when at full capacity. The CMS reimbursement rate per PCR test is $100, and best practices indicate that labs can bill for an additional PCR test to confirm the variant associated with a positive when using the Kogene Variant Kit. To date, over 37 million people in the United States have tested positive for COVID-19, and with the rate of breakthrough infections rapidly increasing, tracking variants of interest and of concern is now urgently needed.
https://investor.todosmedical.com/news-events/press-releases/detail/127/todos-medicals-cliacap-lab-provista-completes
Note: Amarantus shareholders have a stake in Todos Medical
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants
• Company sees a significant market opportunity for reference lab agreements to identify which variant is responsible for positive COVID-19 test results
• Validation paves the way for launch of variant testing at Provista in September 2021
New York, NY, and Tel Aviv, ISRAEL, Aug. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the Kogene Biotech PCR Variant Test Kit (‘Kogene Variant Kit’) into production and expects to launch variant testing in September 2021. The Kogene Variant Kit is a PCR kit capable of identifying the key mutations associated with specific SARS-CoV-2 variants, including the key P681R mutation identified in the Delta variant, that allows Todos to categorize the lineage of the strain responsible for a positive test result. The test can be completed in as little as one hour, significantly faster than genome sequencing, and is highly scalable with the Tecan® liquid handling automation currently onsite at Provista.
“With the rising number of breakthrough infections caused by the Delta variant that now represents approximately 96% of cases, up from 3% in early July 2021, it has become extremely clear that the United States’ genomic sequencing capabilities are unable to keep up with the sheer volume of demand for classifying which variants are responsible for SARS-CoV-2 infections,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Not only is there significant public health interest in tracking variants, there is also an emerging clinical difference in how physicians may speed the prescription of certain treatments based upon which variant a patient has. This clinical utility, initially seen with the Alpha variant and now more pronounced with the Delta variant, means that we must prepare for the future where we expect new variants, such as the Lambda variant, that appear more capable of escaping vaccination protection and may result in more aggressive treatment strategies. The ability for Provista to scale this test offering rapidly with our automation by reflexing positives for variant analysis and by expanding our reference lab network to confirm which variants are responsible for other labs’ positive results will improve regional understanding of the spread of new variants as they emerge, and provide schools, businesses, and public health officials an ability to react more quickly with policy changes.”
Todos sees a large market opportunity developing for variant testing that will further expand upon the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 PCR tests, over 1,500 cPass tests per day and can complete over 5,000 variant tests per day when at full capacity. The CMS reimbursement rate per PCR test is $100, and best practices indicate that labs can bill for an additional PCR test to confirm the variant associated with a positive when using the Kogene Variant Kit. To date, over 37 million people in the United States have tested positive for COVID-19, and with the rate of breakthrough infections rapidly increasing, tracking variants of interest and of concern is now urgently needed.
https://investor.todosmedical.com/news-events/press-releases/detail/127/todos-medicals-cliacap-lab-provista-completes
Todos Medical to launch its cPass blood test that tests for antibodies in September this year
Todos Medical Ltd CEO Gerald Commissiong caught up with Proactive New York to talk about its expectation to launch the group's cPass blood test in September this year, which could play a key role in the USA's rollout of coronavirus booster jabs.
Commissiong says it comes after the firm's certified lab Provista Diagnostics successfully completed the validation studies required to put the cPass neutralizing antibody blood test into production. Todos sees a large market opportunity developing for cPass that will expand upon the coronavirus PCR testing market that rapidly developed into a worldwide $80 billion market last year.
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers
Note: Amarantus shareholders have a stake in Todos Medical
https://investor.todosmedical.com/news-events/press-releases/detail/126/todos-medicals-cliacap-lab-provista-enters-into
Agreement will enable Meadowlands Diagnostics to offer cPass testing for COVID-19 immunity monitoring to its growing customer base including two additional New Jersey School system contracts
New York, NY, and Tel Aviv, ISRAEL, Aug. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has entered into a reference lab agreement to provide cPass neutralizing antibody blood testing services to Meadowlands Diagnostics, a CLIA-certified New Jersey-based provider of laboratory testing services.
Reference lab agreements enable the movement of specimens between labs in order to perform specialized testing that the ordering lab doesn’t have the ability to run in-house. The cPass ELISA blood test has received Emergency Use Authorization from the FDA for the detection of neutralizing antibodies (NAbs) that will allow healthcare professionals and patients to monitor key biomarkers of COVID-19 immunity. Todos has successfully completed the validation studies required to put the cPass Neutralizing Antibody Blood Test for semi-quantitative detection of NAbs into production and expects to begin conducting tests for reference laboratory clients beginning in September 2021. To get more information on the cPass test today please visit Provista’s website www.provistadx.com.
Reginald Samuels, President & CEO of Meadowlands Diagnostics commented, “We see the ability to offer cPass testing as a key differentiator for Meadowlands as we continue to win and pursue COVID related testing contracts in the education, government, and business spaces. Todos has already equipped us with automation and testing consumables for our PCR testing services that has enabled us to win two school district testing contracts in New Jersey that begin testing in the coming weeks, so this reference agreement is a natural progression for our relationship together. We also share a similar vision that immunity monitoring will be critical in determining the need for vaccine boosters or other measures to prevent virus spread. We are excited to be ahead of the curve to begin offering this FDA EUA cleared test to our existing and potential customers, and we look forward to continuing to grow our relationship with Todos.”
Gerald Commissiong, President & CEO of Todos, added, “Providing EUA authorized cPass testing as a reference lab service to CLIA labs across the country is an important component of our COVID-19 immunity monitoring strategy, and we look forward to working with Meadowlands to open this significant market opportunity for both our companies. By having the ability to take reference samples from labs all over the country we are able to leverage those labs’ existing customer bases to win business. Based on the inquiries for cPass received after news of cPass’ validation was made public yesterday, it’s become clear that our automation will serve us well as we capture the significant demand from clinicians and patients. Having this capacity, which we can continue to build well beyond 1,500 cPass tests per day, will allow us to scale the cPass business in a cost efficient manner. We continue to optimize our capabilities to do high volume PCR testing at Provista and look forward to cPass helping drive significant revenue growth for Todos in the coming quarters. We will be focused on reference lab agreements for COVID T-PCR, cPass and COVID variant testing, which we expect to complete validation for in the near future.”
Mr. Commissiong continued, “The pending decision to allow booster shots in the United States at the 8-month point was strongly rebuked by WHO Director-General Tedros Adhanom Ghebreyeses, who called for a two-month moratorium on COVID-19 booster shots in order to enable low and middle-income countries the opportunity to provide vaccines to their citizens. The logical path forward to compromise on this issue is to ensure that the booster shots, which will be in high demand given that the US government has already signaled its intent, be prioritized for the many people that need it whose NAs titers show waning immunity. The cPass test is uniquely capable of identifying which vaccinated individuals need the booster. We look forward to taking a leadership position in helping policy makers make data driven decisions and ensuring that booster shots at least go to those with waning NAbs.”
Provista Diagnostics has the automation in place to do up to 20,000 PCR tests and over 1,500 cPass tests per day. The CMS reimbursement rate per PCR test is $100 and per cPass test is at least $79. Immune monitoring will likely be the primary driver of COVID-19 testing growth in this multi-billion market going forward. To date, over 200 million people in the United States have received at least one COVID-19 vaccine dose, with the majority of the doses having been administered to older populations and the immunocompromised for whom booster shots are being recommended. As time advances, and more and more individuals are 6 months and beyond from full vaccination, it will become increasingly important for individuals, schools, businesses and healthcare providers to asses and monitor NAb levels in order to make data-driven decisions with respect to booster shots and behavioral changes.
Todos Medical CEO Gerald Commissiong on Fox Business News
Watch Todos Medical CEO Gerald Commissiong discuss cPass neutralizing antibody test for COVID19.
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
Note: Amarantus shareholders have a stake in Todos Medical
https://investor.todosmedical.com/news-events/press-releases/detail/125/todos-medical-completes-validation-of-cpass-neutralizing
• Company sees a significant market opportunity for cPass as a potential immunity monitoring tool for schools, businesses and healthcare providers to determine the future need for booster shots or other measures to prevent virus spread
• CEO to discuss cPass on Fox Business Network ‘Varney & Company’ at 11:40 am on August 23, 2021
• Validation paves the way for launch of cPass testing at Provista in September 2021
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the cPass Neutralizing Antibody Blood Test into production and expects to launch cPass in September 2021. The cPass ELISA blood test has received Emergency Use Authorization from the FDA for the detection of neutralizing antibodies (NAbs) that will allow healthcare professionals and patients to monitor key biomarkers of COVID-19 immunity.
Todos Medical CEO Gerald Commissiong has been scheduled to appear on Fox Business Network show Varney & Company at 11:40 am ET on Monday, August 23, 2021 to discuss cPass and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States. There are a rising number of breakthrough infections and the cPass may represent a way to identify those at greatest risk.
“As we begin to see the impact of breakthrough infections with the Delta variant throughout the United States, we expect the FDA to authorize widespread access to booster shots in the weeks ahead,” said Gerald Commissiong, President & CEO of Todos Medical. “Vaccinated and unvaccinated patients are certainly looking for solutions to understand their level of risk to the Delta variant. Likewise, many physicians are looking for objective data to help them manage their patients. cPass will help provide this key information on neutralizing antibody levels in vaccinated patients and patients that acquired their immunity through natural infection. The test allows both the patient and the physician to be more informed with respect to the patient’s existing level of COVID-19 immunity. The White House push to get people vaccinated quickly in the second quarter displaced the testing volume that was expected by many COVID testing labs and so they retooled back to their pre-pandemic business models centered on non-COVID sample volume. We chose a different path for Provista and sought to invest in automation to prepare for the next wave of the disease and the tremendous monitoring opportunity we felt it represented. We saw our local community in the greater Atlanta area ravaged by the first and second waves of the disease due to a lack of testing capability, and felt we had an obligation to be more proactive to fulfill the market need just as schools and business prepare to open for the fall. We think cPass could play a pivotal role in helping roll out booster shots to those at-risk in the months ahead.
Todos sees a large market opportunity developing for cPass that will expand upon the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 PCR tests and over 1,500 cPass tests per day. The CMS reimbursement rate per PCR test is $100 and per cPass test is at least $79. Immune monitoring will likely be the primary driver of COVID-19 testing growth going forward. To date, over 200 million people in the United States have received at least one COVID-19 vaccine dose, with the majority of the doses having been administered to older populations and the immunocompromised for whom booster shots are being recommended. As time advances, and more and more individuals are 6 months and beyond from their initial vaccine dose, it will become increasingly important for individuals, schools, businesses and healthcare providers to asses and monitor neutralizing antibody levels in order to make data-driven decisions with respect to booster shots and behavioral changes.
leslunier, the Provista Diagnostic options were executed. After I provide proof in the filings, I hope this satisfies your continuing suspicions that GC is lying to shareholders. There are numerous examples of where this was reported and supported in the various filings. No more questions, as I am done researching this to address your concerns. There is still the question of how $3M + $7.5M adds to $10M, but I did see reference throughout to a number of smaller amounts and fees paid to Provista that were likely credited to the final price, so I suspect that's where the $0.5M difference lies. I spent way too much time on this already and I'm not going to dig those up to try explain the difference. Doesn't matter to me. I'm satisfied the transaction was legit. No more questions, please.
This is the timeline of relevant filings and events.
1/9/20
News release announcing option to acquire Provista Diagnostics
https://investor.todosmedical.com/news-events/press-releases/detail/35/todos-medical-enters-into-exclusive-option-agreement-to
1/10/20
Form 6-K filing describing Provista Diagnostics acquisition price of $10M.
- $1M paid for consideration of option to acquire, expiring 3/31/20
- $1M additional payment required to extend option to 6/30/20
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001213900-20-000685/0001213900-20-000685.pdf
2/1/20
Schedule 13G filed by Strategic Investment Holdings listing ownership of 17,096,096 Todos shares.
Transaction date is 1/21/20. Total ownership listed as 17,091,096 shares.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-002837/0001493152-20-002837.pdf
4/10/20
Schedule 13G filed by Strategic Investment Holdings listing ownership of another 13,008,976 Todos shares.
Transaction date is 4/1/20. Total ownership listed as 30,100,072 shares.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-006190/0001493152-20-006190.pdf
5/11/20
Form 6-K filed providing voting results of the Special Meeting of Shareholders. Proposal 2 is approved:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-008246/0001493152-20-008246.pdf
6/15/20
Form 20-F (Annual Report) filed.
From page 95:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-011206/0001493152-20-011206.pdf
7/15/20
Schedule 13D filed by Strategic Investment Holdings listing ownership of another 18,608,113 Todos shares.
Transaction date is 7/7/20. Total ownership is listed as 48,708,185 shares.
I assume this is the option to extend acquisition deadline to 2021. Look to future filings for explanation.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-20-013368/0001493152-20-013368.pdf
4/21/21
Form 10-K (Annual Report) filed.
From page F-64:
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-009396/0001493152-21-009396.pdf
The 3 filings of share ownership by Strategic Investment Holdings align with the 3 option payments of $1M each. Again, I expect the full explanation of this acquisition to be in the upcoming quarterly report.
werd, your posts suggest you believe Pfizer understands the molecular target of the 3CL protease enzyme better than Todos. Fact is, Todos partnered with NLC Pharma, which probably has as much experience and research with the 3C and 3CL protease enzymes as does Pfizer. It is my belief they are at least on even footing, and perhaps the NLC Pharma joint venture gives Todos the advantage over Pfizer, since the Tollovir product has also been shown to suppress the cytokine storm that is a dangerous immune system response.
I do agree with you, however, that a buyout offer may be at least a possibility, but probably after trial results are published (but then at a much higher price if results are good).
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity
https://investor.todosmedical.com/news-events/press-releases/detail/125/todos-medical-completes-validation-of-cpass-neutralizing
• Company sees a significant market opportunity for cPass as a potential immunity monitoring tool for schools, businesses and healthcare providers to determine the future need for booster shots or other measures to prevent virus spread
• CEO to discuss cPass on Fox Business Network ‘Varney & Company’ at 11:40 am on August 23, 2021
• Validation paves the way for launch of cPass testing at Provista in September 2021
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its CLIA/CAP certified lab Provista Diagnostics has successfully completed the validation studies required to put the cPass Neutralizing Antibody Blood Test into production and expects to launch cPass in September 2021. The cPass ELISA blood test has received Emergency Use Authorization from the FDA for the detection of neutralizing antibodies (NAbs) that will allow healthcare professionals and patients to monitor key biomarkers of COVID-19 immunity.
Todos Medical CEO Gerald Commissiong has been scheduled to appear on Fox Business Network show Varney & Company at 11:40 am ET on Monday, August 23, 2021 to discuss cPass and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States. There are a rising number of breakthrough infections and the cPass may represent a way to identify those at greatest risk.
“As we begin to see the impact of breakthrough infections with the Delta variant throughout the United States, we expect the FDA to authorize widespread access to booster shots in the weeks ahead,” said Gerald Commissiong, President & CEO of Todos Medical. “Vaccinated and unvaccinated patients are certainly looking for solutions to understand their level of risk to the Delta variant. Likewise, many physicians are looking for objective data to help them manage their patients. cPass will help provide this key information on neutralizing antibody levels in vaccinated patients and patients that acquired their immunity through natural infection. The test allows both the patient and the physician to be more informed with respect to the patient’s existing level of COVID-19 immunity. The White House push to get people vaccinated quickly in the second quarter displaced the testing volume that was expected by many COVID testing labs and so they retooled back to their pre-pandemic business models centered on non-COVID sample volume. We chose a different path for Provista and sought to invest in automation to prepare for the next wave of the disease and the tremendous monitoring opportunity we felt it represented. We saw our local community in the greater Atlanta area ravaged by the first and second waves of the disease due to a lack of testing capability, and felt we had an obligation to be more proactive to fulfill the market need just as schools and business prepare to open for the fall. We think cPass could play a pivotal role in helping roll out booster shots to those at-risk in the months ahead.
Todos sees a large market opportunity developing for cPass that will expand upon the COVID-19 PCR testing market that rapidly developed into an $80 billion market worldwide in 2020. Provista Diagnostics has the automation in place to do up to 20,000 PCR tests and over 1,500 cPass tests per day. The CMS reimbursement rate per PCR test is $100 and per cPass test is at least $79. Immune monitoring will likely be the primary driver of COVID-19 testing growth going forward. To date, over 200 million people in the United States have received at least one COVID-19 vaccine dose, with the majority of the doses having been administered to older populations and the immunocompromised for whom booster shots are being recommended. As time advances, and more and more individuals are 6 months and beyond from their initial vaccine dose, it will become increasingly important for individuals, schools, businesses and healthcare providers to asses and monitor neutralizing antibody levels in order to make data-driven decisions with respect to booster shots and behavioral changes.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain (COVID-19) testing materials and supplies. The agreements cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity
https://investor.todosmedical.com/news-events/press-releases/detail/124/todos-medical-ceo-to-appear-on-fox-business-network-varney
New York, NY, and Tel Aviv, ISRAEL, Aug. 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that Gerald Commissiong, CEO of Todos Medical, is scheduled to appear on Varney & Co. on the Fox Business Network at 11:40 AM Eastern Time today. Mr. Commissiong will discuss the planned launch of cPass neutralizing antibody testing at the Company’s Provista Diagnostics laboratory and how it is expected to empower healthcare professionals and patients with a new tool to monitor their immunity to COVID-19 as booster shots are being rolled out in the United States.
The segment can also be viewed online at: Varney & Co| Fox Business.
Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM – 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts.
About Todos Medical Ltd.
Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista's proprietary commercial-stage Videssa® breast cancer blood test.
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos has entered into distribution agreements with companies to distribute certain (COVID-19) testing materials and supplies. The agreements cover multiple suppliers of PCR testing kits, extraction kits, automation materials and supplies, as well as COVID-19 antibody and antigen testing kits.
Todos has entered into a joint venture with NLC Pharma to pursue the development of diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors that target a fundamental reproductive mechanism of coronaviruses.
For more information, please visit https://www.todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.
Todos Corporate and Investor Contact:
Richard Galterio
Todos Medical
732-642-7770
rich.g@todosmedical.com
You have the option to skip over those posts, as they are clearly labeled as CEO on Twitter with the date. I intend to continue to post CEO tweets here because they are relevant to the company's business. Some readers here do not have Twitter accounts, including yourself. No one is forcing your to read those Twitter posts.
One would think you would welcome the Twitter reposts, as it provides additional things to pick apart to support the theory that GC is lying to us. It must be difficult being a shareholder in a company where one believes the CEO is lying to shareholders, and yet continuing to hold shares, unable to sell and move on. I can only imagine the stress that creates.
Or, just put me on IGNORE as I've suggested. i don't care which. Either option requires some amount of self control. Perhaps that's the real issue.
So now you don't want to see GC's Twitter posts here?
You keep posting twitter tweets that GC posts. This is TODOS board not twitter.